Protocol Ledger

NCT03648489 · Phase II · COMPLETED

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Interventional Phase II clinical trial protocol NCT03648489 sponsored by Imperial College London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-21 Enrollment: 134 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03648489
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)134 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03648489
Protocol FieldVerified Registry Value
NCT IdentifierNCT03648489
Consolidated Lead SponsorImperial College London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment134 participants (ACTUAL)
Registered Start Date2018-09-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03648489
Hospital Research SiteLocationSite Profile
Charité Universitätsmedizin BerlinBerlin, GermanyOpen Hospital Dossier ->
The Royal Marsden NHS Foundation TrustLondon, United KingdomOpen Hospital Dossier ->
Imperial College Healthcare NHS TrustLondon, United KingdomOpen Hospital Dossier ->
The Christie NHS Foundation TrustManchester, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI